MX2012007754A - Derivados de pirazina y su uso en el tratamiento de transtornos neurologicos. - Google Patents

Derivados de pirazina y su uso en el tratamiento de transtornos neurologicos.

Info

Publication number
MX2012007754A
MX2012007754A MX2012007754A MX2012007754A MX2012007754A MX 2012007754 A MX2012007754 A MX 2012007754A MX 2012007754 A MX2012007754 A MX 2012007754A MX 2012007754 A MX2012007754 A MX 2012007754A MX 2012007754 A MX2012007754 A MX 2012007754A
Authority
MX
Mexico
Prior art keywords
treatment
neurological disorders
pyrazine derivatives
pyrazine
derivatives
Prior art date
Application number
MX2012007754A
Other languages
English (en)
Inventor
Marina Tintelnot-Blomley
Siem Jacob Veenstra
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012007754(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2012007754A publication Critical patent/MX2012007754A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a novedosos compuestos heterocíclicos de la fórmula (I): (Ver Formula) en donde todas las variables son como se definen en la memoria descriptiva, en forma libre o en forma de sal, a su preparación, a su uso médico, y a medicamentos que los comprenden.
MX2012007754A 2009-12-31 2010-12-22 Derivados de pirazina y su uso en el tratamiento de transtornos neurologicos. MX2012007754A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29172409P 2009-12-31 2009-12-31
PCT/EP2010/070502 WO2011080176A1 (en) 2009-12-31 2010-12-22 Pyrazine derivatives and their use in the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
MX2012007754A true MX2012007754A (es) 2012-08-01

Family

ID=43598456

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007754A MX2012007754A (es) 2009-12-31 2010-12-22 Derivados de pirazina y su uso en el tratamiento de transtornos neurologicos.

Country Status (27)

Country Link
US (2) US20120277244A1 (es)
EP (1) EP2519515B1 (es)
JP (1) JP5600754B2 (es)
KR (1) KR101419157B1 (es)
CN (1) CN102712621B (es)
AU (1) AU2010338365B2 (es)
BR (1) BR112012015916A2 (es)
CA (1) CA2785341A1 (es)
CL (1) CL2012001762A1 (es)
CR (1) CR20120332A (es)
CU (1) CU20120099A7 (es)
EA (1) EA201200952A1 (es)
EC (1) ECSP12012065A (es)
ES (1) ES2445536T3 (es)
GT (1) GT201200219A (es)
HN (1) HN2012001413A (es)
IL (1) IL220268A0 (es)
MX (1) MX2012007754A (es)
NZ (1) NZ600136A (es)
PE (1) PE20121640A1 (es)
PH (1) PH12012501007A1 (es)
PL (1) PL2519515T3 (es)
PT (1) PT2519515E (es)
SG (1) SG181431A1 (es)
TN (1) TN2012000249A1 (es)
WO (1) WO2011080176A1 (es)
ZA (1) ZA201203614B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2628074C (en) 2005-10-25 2014-01-14 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
JP5383484B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 環式基で置換されたアミノジヒドロチアジン誘導体
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
MX2012006491A (es) 2009-12-11 2012-07-03 Shionogi & Co Derivados de oxazina.
MX2012014382A (es) * 2010-06-09 2013-01-29 Janssen Pharmaceutica Nv Derivados de 5-amino-3, 6-dihidro-1h-pirazin-2-ona utiles como inhibidores de beta-secretasa (bace).
MX339640B (es) 2010-06-09 2016-06-01 Janssen Pharmaceutica Nv * Derivados de 5, 6-dihidro-2h-[1, 4] oxazin-3-il-amina utiles como inhibidores de la beta-secretasa (bace).
US20130102618A1 (en) * 2010-06-28 2013-04-25 Janssen Pharmaceutica Nv 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatment of alzheimer's disease and other forms of dementia
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
EP2655376B1 (en) 2010-12-22 2017-08-23 Janssen Pharmaceutica NV 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
MY162413A (en) 2011-01-13 2017-06-15 Novartis Ag Novel heterocyclic derivatives and their use in the treatment of neurological disorders
JP2014505689A (ja) * 2011-01-13 2014-03-06 ノバルティス アーゲー 代謝障害の処置用ｂａｃｅ−２阻害剤
CN103415519B (zh) 2011-03-01 2016-03-02 詹森药业有限公司 作为β-分泌酶(BACE)抑制剂有用的6，7-二氢-吡唑[1，5-a]吡嗪-4-基胺衍生物
AU2012224632B2 (en) 2011-03-09 2016-06-16 Janssen Pharmaceutica Nv 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
BR112013026341A2 (pt) 2011-04-13 2019-09-24 Merck Sharp & Dohe Corp composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
CN103874496A (zh) 2011-08-22 2014-06-18 默沙东公司 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
EP2934539B1 (en) 2012-12-20 2019-03-27 Merck Sharp & Dohme Corp. C5, c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors
KR102243134B1 (ko) 2013-06-12 2021-04-22 얀센 파마슈티카 엔.브이. 베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-5,6-디하이드로이미다조[1,5-a]피라진 유도체
BR112015030597A2 (pt) 2013-06-12 2017-07-25 Janssen Pharmaceutica Nv derivados 4-amino-6-fenil-6,7-di-hidro[1,2,3]triazolo[1,5-a]pirazina como inibidores de beta-secretase (bace)
MX368326B (es) 2013-06-12 2019-09-27 Janssen Pharmaceutica Nv Derivados de 4-amino-6-fenil-5,6-dihidroimidazo[1,5-a]pirazin-3(2h )-ona como inhibidores de beta-secretasa (bace).
ES2768823T3 (es) 2014-12-18 2020-06-23 Janssen Pharmaceutica Nv Derivados de 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2H-pirrol-5-amina útiles como inhibidores de beta-secretasa
CN107011134B (zh) * 2017-04-28 2021-02-05 浙江中欣氟材股份有限公司 一种2-氟-5-溴苯乙酮的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6911868A (es) 1968-08-31 1970-03-03
AUPQ319899A0 (en) * 1999-10-01 1999-10-28 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
BRPI0418212A (pt) 2003-12-29 2007-04-27 Banyu Pharma Co Ltd composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade
US20050215884A1 (en) * 2004-02-27 2005-09-29 Greicius Michael D Evaluation of Alzheimer's disease using an independent component analysis of an individual's resting-state functional MRI
CA2628074C (en) * 2005-10-25 2014-01-14 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
EP1945632B1 (en) * 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
CN101568529A (zh) * 2006-12-22 2009-10-28 诺瓦提斯公司 作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物
PL2233474T3 (pl) 2008-01-18 2015-12-31 Eisai R&D Man Co Ltd Skondensowana pochodna aminodihydrotiazyny
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
UY32799A (es) * 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
MX2012014382A (es) * 2010-06-09 2013-01-29 Janssen Pharmaceutica Nv Derivados de 5-amino-3, 6-dihidro-1h-pirazin-2-ona utiles como inhibidores de beta-secretasa (bace).
US20130102618A1 (en) * 2010-06-28 2013-04-25 Janssen Pharmaceutica Nv 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatment of alzheimer's disease and other forms of dementia

Also Published As

Publication number Publication date
CL2012001762A1 (es) 2012-12-21
ZA201203614B (en) 2013-01-30
TN2012000249A1 (en) 2013-12-12
GT201200219A (es) 2013-10-10
WO2011080176A1 (en) 2011-07-07
ES2445536T3 (es) 2014-03-03
PL2519515T3 (pl) 2014-04-30
NZ600136A (en) 2013-09-27
CN102712621B (zh) 2015-03-11
US20120277244A1 (en) 2012-11-01
CR20120332A (es) 2012-07-12
BR112012015916A2 (pt) 2017-04-25
EP2519515B1 (en) 2013-11-06
CN102712621A (zh) 2012-10-03
EA201200952A1 (ru) 2013-02-28
PE20121640A1 (es) 2012-12-17
KR20120102795A (ko) 2012-09-18
AU2010338365A1 (en) 2012-06-07
EP2519515A1 (en) 2012-11-07
JP2013516395A (ja) 2013-05-13
CA2785341A1 (en) 2011-07-07
SG181431A1 (en) 2012-07-30
CU20120099A7 (es) 2012-07-31
HK1172023A1 (en) 2013-04-12
US20150322038A1 (en) 2015-11-12
JP5600754B2 (ja) 2014-10-01
PH12012501007A1 (en) 2013-01-14
IL220268A0 (en) 2012-07-31
AU2010338365B2 (en) 2014-01-30
HN2012001413A (es) 2015-03-23
PT2519515E (pt) 2014-02-17
ECSP12012065A (es) 2012-08-31
KR101419157B1 (ko) 2014-07-11

Similar Documents

Publication Publication Date Title
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
MX2012001070A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos.
PH12013501600A1 (en) Novel heterocyclic derivatives
TN2012000067A1 (en) Oxazine derivatives and their use in the treatment of neurological disorders
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
MX2012002179A (es) Compuestos heterociclicos de oxima.
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
TN2014000175A1 (en) Novel purine derivatives and their use in the treatment of disease
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
UA98961C2 (uk) Похідні піразинону та їх застосування у лікуванні легеневих захворювань
MX2012001838A (es) Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX339302B (es) 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX2010002007A (es) Sulfonas ciclicas sustituidas por amino-bencilo utiles como inhibidores de bace.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MX2014003455A (es) Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide.
GB0602951D0 (en) Organic Compounds
PH12012501521A1 (en) 5-alkynyl pyrimidines and their use as kinase inhibitors
MA33958B1 (fr) Derives de pyrazine et leur utilisation dans le traitement de troubles neurologiques

Legal Events

Date Code Title Description
FG Grant or registration